Table 5.
Compound | Relation | Value | Unit | Standard | Assay | Cell Line | Source |
---|---|---|---|---|---|---|---|
BA | > | 10 | µmol/L | IC50 | Cytotoxicity against human cells after 48 h by SRB assay | BT-549 | [164] |
> | 10 | µmol/L | IC50 | A549 | [164] | ||
> | 10 | µmol/L | IC50 | SK-MEL-2 | [164] | ||
> | 50 | µmol/L | IC50 | Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 h by Griess assay | BV-2 | [164] | |
> | 10 | µmol/L | IC50 | Cytotoxicity against human SKOV3 cells after 48 h by SRB assay | SK-OV-3 | [164] | |
CinA | = | 64 | µmol/L | IC50 | Anticancer activity against human cells after 48 h by MTT assay | A-375 | [165] |
= | 108 | µmol/L | IC50 | MCF7 | [165] | ||
= | 91 | µmol/L | IC50 | ACHN | [165] | ||
= | 87 | µmol/L | IC50 | A549 | [165] | ||
= | 114 | µmol/L | IC50 | HT-29 | [165] | ||
> | 100 | µmol/L | IC50 | Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 h in presence of LPS by Griess assay | BV-2 | [165] | |
p-CA | > | 100 | µmol/L | IC50 | Cytotoxicity against human SK-MEL-28 cells after 72 h by MTT assay | SK-MEL-28 | [166] |
> | 100 | µmol/L | IC50 | Cytotoxicity against human A549 cells after 72 h by MTT assay | A549 | [166] | |
> | 10 | µmol/L | IC50 | Cytotoxicity against human SKOV3 cells after 48 h by SRB assay | SK-OV-3 | [164] | |
= | 10 | µmol/L | IC50 | Cytotoxicity against human BT549 cells after 48 h by SRB assay | BT-549 | [164] | |
> | 2000 | µmol/L | IC50 | Antiproliferative activity against human U937 cells assessed as incorporation of methyl-3H-thymidine after 12 h by scintillation counting | U-937 | [167] | |
> | 200 | µmol/L | IC50 | Antitumor activity against KB cells by MTT assay | KB | [168] | |
= | 82 | µmol/L | IC50 | Cytotoxicity against human LoVo cells after 72 h by MTT assay | LoVo | [166] | |
> | 10 | µmol/L | IC50 | Cytotoxicity against human A549 cells after 48 h by SRB assay | A549 | [164] | |
> | 100 | µmol/L | IC50 | Cytotoxicity against human PC3 cells after 72 h by MTT assay | PC-3 | [166] | |
> | 10 | µmol/L | IC50 | Cytotoxicity against human SK-MEL-2 cells after 48 h by SRB assay | SK-MEL-2 | [164] | |
CFA | = | 317 | µmol/L | IC50 | Antiproliferative activity against human U937 cells assessed as incorporation of methyl-3H-thymidine after 12 h by scintillation counting | U-937 | [167] |
= | 700 | µmol/L | IC50 | Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 h by luminescence-based ATP assay | A549 | [167] | |
= | 6.4 | µmol/L | IC50 | Antiproliferative activity against human MOLM13 cells by CellTiter-Glo assay | MOLM-13 | [169] | |
= | 500 | µmol/L | IC50 | Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 h by FMCA assay | A549 | [167] | |
= | 30 | µmol/L | IC50 | Cytotoxicity against human HCT116 cells after 96 h by MTT assay | HCT-116 | [170] | |
> | 10 | µmol/L | IC50 | Antiproliferative activity against human MV4-11 cells by CellTiter-Glo assay | MV4-11 | [169] | |
= | 76 | µmol/L | IC50 | Neuroprotection against amyloid beta (25 to 35)-induced cell death in rat PC12 cells pre-incubated for 3 h followed by amyloid beta addition measured after 24 h by MTT assay | PC-12 | [171] | |
- | - | - | IC50 | Activity against hydrogen peroxide induced DNA damage in Jurkat T cells | Jurkat | [172] | |
= | 27 | µmol/L | IC50 | Cytotoxicity against human HT-29 cells after 96 h by MTT assay | HT-29 | [170] | |
= | 700 | µmol/L | IC50 | Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 h by MTT assay | A549 | [167] | |
> | 550 | µmol/L | IC50 | Cytotoxicity against African green monkey Vero cells assessed as [3H]-hypoxanthine incorporation after 48 h | Vero | [173] | |
> | 550 | µmol/L | IC50 | Cytotoxicity against human MCF7 cells assessed as [3H]-hypoxanthine incorporation after 48 h | MCF7 | [173] | |
= | 129 | µmol/L | IC50 | Cytotoxicity against human AGS cells after 96 h by MTT assay | AGS | [170] | |
= | 940 | µmol/L | IC50 | Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pre-treated for 10 min with normal human serum followed by erythrocyte addition measured after 30 min by spectrophotometric method | Erythrocyte | [174] | |
= | 44.0 | µg/mL | IC50 | Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA | HeLa | [175] | |
= | 0.002 | µmol/L | IC50 | Antiproliferative activity against human T47D cells after 5 days by MTT assay | T47D | [176] | |
= | 750 | µmol/L | IC50 | Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pre-treated for 10 min with guinea pig serum followed by erythrocyte addition measured after 30 min by spectrophotometric method | Erythrocyte | [174] | |
> | 100 | µmol/L | IC50 | Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 24 h by WST-1 assay | LNCaP | [177] | |
> | 100 | µmol/L | IC50 | Antiproliferative activity against human A549 cells after 72 h by MTT assay | A549 | [178] | |
> | 10 | µmol/L | IC50 | Antiproliferative activity against human MOLM14 cells by CellTiter-Glo assay | MOLM-14 | [169] | |
RA | = | 40.4 | % | Inhibition | Inhibition of Jurkat cell activation assessed as blocking of T-cell antigen receptor-induced IL-2 expression at 10 µmol/L by luciferase assay | Jurkat | [179] |
= | 50 | % | Inhibition | Inhibition of Jurkat cell activation assessed as blocking of T-cell antigen receptor-induced IL-2 expression at 30 µmol/L by luciferase assay | Jurkat | [179] | |
- | - | - | Activity | Cytotoxicity against human HepG2 cells up to 20 µmol/L after 24 h by MTS assay | HepG2 | [180] | |
= | 71 | % | Activity | Inhibition of cell proliferation of human U251 cells assessed as cell viability at 100 µmol/L after 72 h by SRB assay | U-251 | [181] | |
= | 27 | % | Inhibition | Inhibition of Wnt/beta-catenin signaling pathway in human HEK293 cells at 20 µmol/L after 24 h by dual luciferase reporter gene assay relative to vehicle-treated control | HEK293 | [182] | |
- | - | - | Activity | Cytoprotection against phototoxicity in human NHDF cells assessed as increase in cell viability at 3.9 to 31.3 µmol/L preincubated for 60 min followed by 7.5 J/cm2 UVA irradiation and measured after 24 h by neutral red uptake assay | NHDF | [183] | |
- | - | - | Activity | Cytoprotection against phototoxicity in human HaCaT cells assessed as increase in cell viability at 3.9 µmol/L preincubated for 60 min followed by 10 J/cm2 UVA irradiation and measured after 24 h by neutral red uptake assay | HaCaT | [183] | |
- | - | - | Activity | Cytoprotection against phototoxicity in human NHDF cells assessed as increase in cell viability at 3.9 to 31.3 µmol/L preincubated for 60 min followed by 150 mJ/cm2 UVB irradiation and measured after 24 h by neutral red uptake assay | NHDF | [183] | |
- | - | - | Activity | Cytoprotection against phototoxicity in human HaCaT cells assessed as increase in cell viability at 3.9 to 31.3 µmol/L preincubated for 60 min followed by 10 J/cm2 UVA irradiation and measured after 24 h by neutral red uptake assay | HaCaT | [183] | |
= | 2.9 | µmol/L | IC50 | Antiproliferative activity against human cells by CellTiter-Glo assay | MOLM-13 | [169] | |
> | 10 | µmol/L | IC50 | MV4-11 | [169] | ||
= | 7.1 | µmol/L | IC50 | MOLM-14 | [169] | ||
= | 55 | µmol/L | CC50 | Cytotoxicity against human MT4 cells by MTT method | MT4 | [184] | |
D-ChA | = | 39.7 | µmol/L | IC50 | Concentration of compound required to reduce MT-4 cell viability by 50% | MT4 | [185] |
= | 35.5 | µmol/L | IC50 | Compound was evaluated for the cytoprotection of CEM-SS cells by XTT cytoprotection assay through the NCI AIDS Screen | CEM-SS | [185] | |
L-ChA | = | 20.1 | µmol/L | IC50 | CEM-SS | [185] | |
= | 45 | µmol/L | IC50 | Concentration of compound required to reduce MT-4 cell viability by 50% | MT4 | [185] | |
D-ChA | = | 111 | µmol/L | CC50 | Cytotoxicity against human MT4 cells by MTT assay | MT4 | [186] |
SRB—sulforhodamine B; MTT—3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; XTT—(2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide).